New research exploring mechanistic benefits of eicosapentaenoic acid (epa) in vitro on lipoprotein(a) [lp(a)] oxidation and on protein expression in endothelial cells in combination with glp-1 receptor agonist to be presented at the american college of cardiology's (acc) annual scientific session & expo

Dublin and bridgewater, n.j., march 19, 2025 (globe newswire) -- amarin corporation plc (nasdaq:amrn) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (epa) will be presented at the american college of cardiology's annual scientific session & expo, march 29-31, 2025, in chicago, il.
ACC Ratings Summary
ACC Quant Ranking